Spearman correlations between change from baseline to week 12 in disease activity parameters and change in structural lesions
| Erosion | Backfill | Fat metaplasia | |||||
| R | p Value | R | p Value | R | p Value | ||
| ASDAS-CRP | ETN, n=83 | 0.40 | <0.001 | −0.26 | 0.018 | −0.10 | 0.352 |
| PBO, n=96 | −0.09 | 0.368 | 0.17 | 0.098 | 0.10 | 0.339 | |
| BASDAI | ETN, n=86 | 0.35 | <0.001 | −0.26 | 0.016 | −0.02 | 0.849 |
| PBO, n=97 | −0.12 | 0.233 | 0.20 | 0.047 | 0.14 | 0.171 | |
| SPARCC MRI SIJ | ETN, n=86 | 0.51 | <0.001 | −0.40 | <0.001 | −0.12 | 0.269 |
| PBO, n=97 | 0.25 | 0.016 | −0.09 | 0.379 | −0.13 | 0.219 | |
| SPARCC spine, 23-DVU | ETN, n=86 | 0.29 | 0.007 | −0.20 | 0.072 | −0.08 | 0.442 |
| PBO, n=97 | −0.04 | 0.674 | −0.04 | 0.735 | −0.11 | 0.299 | |
ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score calculated using C-reactive protein; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BME, bone marrow oedema; DVU, discovertebral unit; ETN, etanercept; PBO, placebo; R, Spearman correlation; SPARCC, Spondyloarthritis Research Consortium of Canada.